|
Synonyms: Abthrax | PAmAb
raxibacumab is an approved drug (FDA (2012))
Compound class:
Antibody
Comment: Raxibacumab is a human IgG1 monoclonal antibody targeting the protective antigen (PA) component of the Bacillus anthracis toxin [2]. It has clinical approval for the prophylaxis and treatment of inhaled anthrax.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes. FDA (2012) |
| International Nonproprietary Names |
|
| INN number | INN |
| 8580 | raxibacumab |
| Synonyms |
| Abthrax | PAmAb |
| Database Links |
|
| Specialist databases | |
Antibiotic DB
|
Raxibacumab |
| IMGT/mAb-DB | 260 |
| Other databases | |
| CAS Registry No. | 565451-13-0 (source: Scifinder) |
| ChEMBL Ligand | CHEMBL2108638 |
| DrugBank Ligand | DB08902 |
| DrugCentral Ligand | 4961 |
| GtoPdb PubChem SID | 496703314 |
| Search PubMed clinical trials | raxibacumab |
| Search PubMed titles | raxibacumab |
| Search PubMed titles/abstracts | raxibacumab |
